Zhuhai Rundu Pharmaceutical (SHE:002923) passed the Good Manufacturing Practice certification from Brazil's health regulator ANVISA for four active pharmaceutical ingredients.
The APIs are candesartan cilexetil, sacubitril valsartan sodium, telmisartan and valsartan, according to a June 28 filing with the Shenzhen bourse.
The certificates are valid through 2027.
Shares of the pharmaceutical company closed less than 1% higher Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments